
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a pre-commercial retina focused biotechnology company using its innovative Antibody Biopolymer Conjugate (ABC) platform to develop transformative therapeutics for retinal diseases. Their investigational medicines, tarcocimab tedromer (Zenkuda or tarcocimab), KSI-501, and KSI-101, have shown promising results in clinical trials and the company has a strong pipeline of late-stage programs. Risks include potential regulatory delays or competition from other biopharmaceutical companies, but the recent positive GLOW2 trial results for Zenkuda and a multi-indication BLA filing have increased confidence in the company's potential for success. With a solid financial position and important data readouts expected in the next few years, Kodiak Sciences has the potential to be a strong player in the retinal medicines market.
Bears say
Kodiak Sciences is facing binary risks surrounding future datasets and could see regulatory delays, as the biotech company's proprietary platform for retinal medicines faces strong competition from established players in the field. While the company's portfolio of investigational medicines shows promise, the success of these drugs is contingent upon positive clinical data and regulatory approval, which may be affected by varying clinical trial protocols among different regulatory agencies. Furthermore, Kodiak's intellectual property may only protect its portfolio until 2030, limiting the company's potential for long-term success.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares